

CLAIMS

1. Use of a composition comprising: (a) 10 mg/mL of Inebilizumab; (b) 20 mM histidine/histidine hydrochloride; (c) 70 mM NaCl; (d) 106 mM trehalose dihydrate; and (e) 0.01% (w/v) polysorbate 80 in the manufacture of a medicament for treating neuromyelitis optica spectrum disorder (NMOSD) in a subject.
2. The use of claim 1, wherein the medicament comprises a pH of 6.
3. The use of claim 1, wherein the composition is to be administered at a dose of 300 mg.
4. The use of claim 1, wherein the medicament is to be administered every 6 months.
5. The use of claim 1, wherein the medicament is effective in reducing worsening of Expanded Disability Status Scale (EDSS) in the subject, as determined by: a worsening of fewer than 2 points in EDSS score if the subject has a baseline score of 0; a worsening of fewer than 1 point if the subject has a baseline score of 1 to 5; or a worsening of less than 0.5 point if the subject has a baseline score of 5.5 or more, when the medicament is to be administered to the subject.
6. The use of claim 1, wherein the medicament is effective in reducing a number of lesions, as determined by magnetic resonance imaging (MRI), when the medicament is to be administered to the subject.
7. The use of claim 6, wherein the lesions are T2 MRI lesions.
8. The use of claim 6, wherein the lesions are new MRI lesions.
9. The use of claim 1, wherein the medicament is effective in reducing worsening of a modified Rankin score when the medicament is to be administered to the subject.
10. The use of claim 1, wherein the medicament is effective in reducing frequency of in-patient hospitalizations related to the NMOSD when the medicament is to be administered to the subject.
11. The use of claim 1, wherein the medicament is effective in reducing risk of an NMOSD-related attack, as determined by appearance of a new symptom of the NMOSD or worsening of an existing symptom of the NMOSD, when the medicament is to be administered to the subject.
12. The use of claim 4, wherein prior to the administration every 6 months an initial administration of the composition is to be administered.
13. The use of claim 12, wherein the initial administration comprises a dosage of 300 mg of Inebilizumab.